Last reviewed · How we verify
GTU®-MultiHIV B Clade Vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
GTU®-MultiHIV B Clade Vaccine (GTU®-MultiHIV B Clade Vaccine) — Imperial College London.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GTU®-MultiHIV B Clade Vaccine TARGET | GTU®-MultiHIV B Clade Vaccine | Imperial College London | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GTU®-MultiHIV B Clade Vaccine CI watch — RSS
- GTU®-MultiHIV B Clade Vaccine CI watch — Atom
- GTU®-MultiHIV B Clade Vaccine CI watch — JSON
- GTU®-MultiHIV B Clade Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). GTU®-MultiHIV B Clade Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/gtu-multihiv-b-clade-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab